292 related articles for article (PubMed ID: 22455492)
1. Biomarkers in community-acquired pneumonia.
Krüger S; Welte T
Expert Rev Respir Med; 2012 Apr; 6(2):203-14. PubMed ID: 22455492
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers in community acquired pneumonia - what did we learn from the CAPNETZ study?].
Krüger S; Pletz MW; Rohde G
Pneumologie; 2011 Feb; 65(2):110-3. PubMed ID: 21117019
[TBL] [Abstract][Full Text] [Related]
3. Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia--a clinical observation in geriatric patients.
Heppner HJ; Bertsch T; Alber B; Esslinger AS; Dragonas C; Bauer JM; Sieber CC
Gerontology; 2010; 56(4):385-9. PubMed ID: 19940454
[TBL] [Abstract][Full Text] [Related]
4. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
5. [A procalcitonin-guided algorithm for pneumonia may reduce antibiotic use and treatment duration].
Berg P; Lindhardt BØ
Ugeskr Laeger; 2012 Aug; 174(35):1986-9. PubMed ID: 22929575
[TBL] [Abstract][Full Text] [Related]
6. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and community-acquired pneumonia: tailoring management with biological data.
Torres A; Ramirez P; Montull B; Menéndez R
Semin Respir Crit Care Med; 2012 Jun; 33(3):266-71. PubMed ID: 22718212
[TBL] [Abstract][Full Text] [Related]
8. Serum procalcitonin level: clinical significance.
Aggarwal D; Mohapatra PR; Aggarwal P
Eur Respir J; 2011 Mar; 37(3):723; author reply 723. PubMed ID: 21357930
[No Abstract] [Full Text] [Related]
9. Procalcitonin and severity of community-acquired pneumonia.
Okimoto N; Hayashi Y; Ishiga M; Nanba F; Kishimoto M; Yagi S; Kurihara T; Asaoka N; Tamada S
J Infect Chemother; 2009 Dec; 15(6):426-7. PubMed ID: 20012738
[TBL] [Abstract][Full Text] [Related]
10. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia.
Póvoa P
Curr Opin Infect Dis; 2008 Apr; 21(2):157-62. PubMed ID: 18317039
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia.
Ramírez P; Ferrer M; Martí V; Reyes S; Martínez R; Menéndez R; Ewig S; Torres A
Crit Care Med; 2011 Oct; 39(10):2211-7. PubMed ID: 21705887
[TBL] [Abstract][Full Text] [Related]
12. [Biomarkers in Diagnosis, Treatment and Prognosis of Infectious Lung Diseases].
Unnewehr M; Kolditz M; Windisch W; Schaaf B
Pneumologie; 2018 May; 72(5):341-346. PubMed ID: 29046011
[TBL] [Abstract][Full Text] [Related]
13. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
14. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
Schuetz P; Litke A; Albrich WC; Mueller B
Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood.
Don M; Valent F; Korppi M; Falleti E; De Candia A; Fasoli L; Tenore A; Canciani M
Scand J Infect Dis; 2007; 39(2):129-37. PubMed ID: 17366029
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
18. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.
Hoshina T; Nanishi E; Kanno S; Nishio H; Kusuhara K; Hara T
J Infect Chemother; 2014 Oct; 20(10):616-20. PubMed ID: 25027057
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.
Jereb M; Kotar T
Wien Klin Wochenschr; 2006 Apr; 118(5-6):170-4. PubMed ID: 16773483
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia.
Porfyridis I; Georgiadis G; Vogazianos P; Mitis G; Georgiou A
Respir Care; 2014 Apr; 59(4):574-81. PubMed ID: 24106319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
